Detalhe da pesquisa
1.
Life Years Gained From the FDA Accelerated Approval Program in Oncology: A Portfolio Model.
J Natl Compr Canc Netw
; : 1-8, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38648848
2.
Cost-effectiveness analysis for avelumab first-line maintenance treatment of advanced urothelial carcinoma in Scotland.
Future Oncol
; 20(8): 459-470, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37529943
3.
Prevalence of Immature Survival Data for Anti-Cancer Drugs Presented to the National Institute for Health and Care Excellence and Impact on Decision Making.
Value Health
; 24(4): 505-512, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33840428
4.
Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses.
BMC Cancer
; 18(1): 1271, 2018 Dec 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-30567533
5.
A cost-effectiveness analysis of avelumab plus best supportive care versus best supportive care alone as first-line maintenance treatment for patients with locally advanced or metastatic urothelial carcinoma in Taiwan.
Cancer Rep (Hoboken)
; 6(10): e1887, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37640556
6.
Incidence-based cost-of-illness model for metastatic breast cancer in the United States.
Int J Technol Assess Health Care
; 28(1): 12-21, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22617734
7.
A Framework for Integrating Continuous Glucose Monitor-Derived Metrics into Economic Evaluations in Type 1 Diabetes.
Pharmacoeconomics
; 40(8): 743-750, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35668248
8.
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
BJU Int
; 108(5): 665-72, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21265994
9.
Treatment costs of prostate cancer in the first year after diagnosis: a short-term cost of illness study for France, Germany, Italy, Spain and the UK.
BJU Int
; 105(1): 49-56, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-20132102
10.
Cost-effectiveness analysis of anastrozole versus tamoxifen in adjuvant therapy for early-stage breast cancer - a health-economic analysis based on the 100-month analysis of the ATAC trial and the German health system.
Onkologie
; 33(4): 155-66, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20389141
11.
A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective.
ESMO Open
; 5(5): e000850, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32998966
12.
An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK.
Pharmacoeconomics
; 27(10): 847-59, 2009.
Artigo
em Inglês
| MEDLINE | ID: mdl-19803539
13.
Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives.
Clinicoecon Outcomes Res
; 11: 659-672, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31807039
14.
Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies.
Pharmacoeconomics
; 37(12): 1537-1551, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31555968
15.
Clinical and economic outcomes associated with treatment sequences in patients with BRAF-mutant advanced melanoma.
Immunotherapy
; 11(4): 283-295, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30563395
16.
Sequential treatment approaches in the management of BRAF wild-type advanced melanoma: a cost-effectiveness analysis.
Immunotherapy
; 10(14): 1241-1252, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30175642
17.
Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States.
Expert Rev Hematol
; 10(12): 1107-1119, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29027825
18.
Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective.
J Med Econ
; 19(11): 1061-1074, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27224006
19.
Cost-Effectiveness of Pazopanib Versus Sunitinib for Renal Cancer in the United States.
J Manag Care Spec Pharm
; 21(9): 834-40, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26308230
20.
Simulation and matching-based approaches for indirect comparison of treatments.
Pharmacoeconomics
; 33(6): 537-49, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795232